My current research focuses on improving outcomes for patients with B-cell lymphomas through translational studies of body composition, including sarcopenia, as predictors of treatment response to CAR T-cell therapy and bispecific antibodies. In parallel, I serve as an institutional principal investigator on a SWOG trial and as a sub-investigator on multiple NCI, cooperative group, and industry-sponsored clinical trials in lymphoma.
In the future, I aim to build on this foundation by continuing to lead NCI, cooperative group, and industry-sponsored studies while also developing investigator-initiated trials that integrate novel agents and biomarkers into CAR T-cell and bispecific strategies. My long-term focus is on optimizing patient selection, reducing treatment-related toxicities, and enhancing the durability of response, with the ultimate goal of improving survival and quality of life for patients with lymphoma.
Fellowship - Moffitt Cancer Center – University of South Florida, Tampa, FL 2021-2024
Residency - Medstar Washington Hospital Center, Washington, DC 2017-2021
M.B.B.S. - B.J. Medical College, Ahmedabad, India 2009-2015
